ArticleBioscience reports2021
The SARS-CoV-2 induced targeted amino acid profiling in patients at hospitalized and convalescent stage.
Article in Bioscience reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- Host metabolic responses to SARS-CoV-2 and influenza viruses: parallels and contrasts.Metabolomics : Official journal of the Metabolomic Society · 2026Review
- Unveiling the role of the upper respiratory tract microbiome in susceptibility and severity to COVID-19.Frontiers in cellular and infection microbiology · 2025Article
- Amino Acid Metabolism in Leukocytes Showing In Vitro IgG Memory from SARS-CoV2-Infected Patients.Diseases (Basel, Switzerland) · 2024Review
- The impact of inflammatory and metabolic markers on depression, anxiety, and cognition after COVID-19: a narrative review.Trends in psychiatry and psychotherapy · 2024Review
- Nanopore membrane chip-based isolation method for metabolomic analysis of plasma small extracellular vesicles from COVID-19 survivors.Biosensors & bioelectronics · 2023Article
- Arginine concentration in arterial vs venous blood in a bleomycin-induced lung inflammation model in mice.PloS one · 2023Article
- Molecular signatures in the progression of COVID-19 severity.Scientific reports · 2022Article
- Association of COVID-19 with hepatic metabolic dysfunction.World journal of virology · 2022Review
- Dissecting the role of the human microbiome in COVID-19 via metagenome-assembled genomes.Nature communications · 2022Article
- Severe COVID-19 Is Characterised by Perturbations in Plasma Amines Correlated with Immune Response Markers, and Linked to Inflammation and Oxidative Stress.Metabolites · 2022Article
- Article
- Alteration of Plasma Amino Acid Concentrations in Iranian Children with COVID-19.International journal of pediatrics · 2022Article
- The snapshot of metabolic health in evaluating micronutrient status, the risk of infection and clinical outcome of COVID-19.Clinical nutrition ESPEN · 2021Review
- Targeted metabolomics identifies high performing diagnostic and prognostic biomarkers for COVID-19.Scientific reports · 2021Article
- Impact of COVID-19 in Liver Disease Progression.Hepatology communications · 2021Review
- Plasma Metabolomic Profiles in Recovered COVID-19 Patients without Previous Underlying Diseases 3 Months After Discharge.Journal of inflammation research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has induced an ongoing global health crisis. Here we utilized a combination of targeted amino acids (AAs) and clinical biochemical profiling to analyze the plasma of coronavirus disease 2019 (COVID-19) subjects at the hospitalization stage and 1-month post-infection convalescent stage, respectively, to investigate the systematic injury during COVID-19 disease progress. We found the virus-induced inflammatory status and reduced liver synthesis capacity in hospitalized patients, which manifested with increased branched-chain AAs (BCAAs), aromatic AAs (AAAs), one-carbon related metabolites, and decreased methionine. Most of these disturbances during infection recover except for the increased levels of medium-chain acylcarnitines (ACs) in the convalescent subjects, implying the existence of incomplete fatty acids oxidation during recovery periods. Our results suggested that the imbalance of the AA profiling in COVID-19 patients. The majority of disturbed AAs recovered in 1 month. The incomplete fatty acid oxidation products suggested it might take longer time for convalescent patients to get complete recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.